Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002340 · ClinicalTrials.gov registry record · Phase 3
A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMX
A Phase 3 study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 3
- Development phase
- 615
- Enrollment target
NCT00002340: Completed Phase 3 study, sponsored by Glaxo Wellcome.
NCT00002340 is a Phase 3 study that has completed, run by Glaxo Wellcome. The registered enrollment target is 615 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002340, a Phase 3 study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 615 participants
- Enrollment target
Study Summary
To assess whether high dose or low dose atovaquone suspension is more effective than aerosolized pentamidine as prophylaxis against Pneumocystis carinii pneumonia (PCP) in high-risk HIV-infected patients. To compare the safety of chronic administration of the three regimens in patients with advanced HIV disease. To determine the relationship between steady state atovaquone plasma concentrations and prophylactic efficacy against PCP.
Interventions
- DRUG Atovaquone
- DRUG Pentamidine isethionate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 615 participants |
| Phase | Phase 3 |
What the finished NCT00002340 record still lists
NCT00002340 is an interventional study that assigns participants to a tested intervention. The registered 615 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 2 interventions - of which Atovaquone is the first listed.
NCT00002340 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002340 about?
NCT00002340 is a clinical study titled "A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMX". To assess whether high dose or low dose atovaquone suspension is more effective than aerosolized pentamidine as prophylaxis against Pneumocystis carinii pneumonia (PCP) in high-risk HIV-infected patients. To compare the safety of chronic administration of the three regimens in patients with advanced...
What is the current status of trial NCT00002340?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 615 participants.
What interventions are being tested in trial NCT00002340?
The interventions under investigation include: Atovaquone (DRUG), Pentamidine isethionate (DRUG).
Who is sponsoring clinical trial NCT00002340?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002340's enrollment target sits among peer trials
615 593rd of 2000 higher than 1,408 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06593652 · 615 participants · NA
Evaluating Caregiver Involvement in Primary Care-Based Brief Interventions for Adolescent Alcohol Use Problems
- NCT04813185 · 616 participants · NA
Preventing Retaliatory Gun Violence in Violently Injured Adults
- NCT06105957 · 616 participants · NA
Optimal Digital Weight Loss Treatment for Rural Individuals
- NCT06162221 · 616 participants · Phase 1
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC